Literature DB >> 8639428

Elevated circulating levels of TNFalpha and its p55 soluble receptor are associated with an adverse prognosis in lymphoma patients.

G Salles1, J Bienvenu, Y Bastion, Y Barbier, C Doche, K Warzocha, M C Gutowski, C Rieux, B Coiffier.   

Abstract

In 88 newly diagnosed lymphoma patients, tumour necrosis factor alpha (TNFalpha) and soluble TNF type I receptor (p55-R-TNF) were prospectively determined in plasma by immunoradiometric assay (IRMA) and ELISA methods respectively. These 88 patients included 19 with centrocyto-centroblastic lymphoma, 13 patients with other low-grade lymphoma, and 56 with high-grade lymphoma. Median TNFalpha plasma values were 20 pg/ml (range 5-380 pg/ml) in patients versus 7 pg/ml (range 4-9 pg/ml) in 20 healthy control subjects. Presence of TNFalpha level > or = 20 pg/ml was significantly associated with elevated LDH level (P<0.0001), serum beta2-microglobulin level > or = 3 mg/l (P<0.0001), haemoglobin < or = 12 g/dl (P=0.0001), Ann Arbor stage III or IV disease (P<0.005), and with bulky tumour (P=0.01). High level of TNFalpha was also associated with B symptoms (P<0.005), poor performance status (P<0.05), and serum albumin < or = 35 g/l (P<0.05). Levels of p55-R-TNF were also markedly elevated in these lymphoma patients (median of 3.5 ng/ml, range 0.8-18.8 ng/ml) versus 1.45 ng/ml in control subjects (range 1.1-2.3 ng/ml). Level of p55-R-TNF > or = 3.5 ng/ml was significantly associated with poor performance status (P<0.0001), B symptoms (P<0.0001), beta2-microglobulin levels > or = 3 mg/l (P<0.0001), serum albumin < or = 35 g/l (P=0.0001), C-reactive protein > 6 mg/l (P=0.0003), elevated (>20 pg/ml) IL-6 level (P<0.005), haemoglobin < or = 12 g/dl (P<0.005), and bulky tumour (P<0.001). In the whole group of 88 patients, both high TNFalpha and p55-R-TNF levels strongly predicted short progression-free survival (P<0.005 for both variables) and overall survival (P<0.001 and P<0.001 respectively). In multivariate analyses the elevation of p55-R-TNF retained a higher significance over the other variables and therefore improved the predictive value of the International Prognostic Index. This study suggests that elevated TNF gamma and p55-R-TNF levels have high correlation with other adverse prognostic factors in lymphoma patients and may predict a poor outcome.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8639428     DOI: 10.1046/j.1365-2141.1996.5181059.x

Source DB:  PubMed          Journal:  Br J Haematol        ISSN: 0007-1048            Impact factor:   6.998


  16 in total

1.  Genetic variants in TNF-α promoter are predictors of recurrence in patients with squamous cell carcinoma of oropharynx after definitive radiotherapy.

Authors:  Caiyun Zhang; Erich M Sturgis; Hongliang Zheng; Xicheng Song; Peng Wei; Lei Jin; Li Chao; Qingyi Wei; Guojun Li
Journal:  Int J Cancer       Date:  2013-10-24       Impact factor: 7.396

Review 2.  TNF-α, a good or bad factor in hematological diseases?

Authors:  Tian Tian; Min Wang; Daoxin Ma
Journal:  Stem Cell Investig       Date:  2014-06-01

3.  Inverse association between brown adipose tissue activation and white adipose tissue accumulation in successfully treated pediatric malignancy.

Authors:  James S Chalfant; Michelle L Smith; Houchun H Hu; Fred J Dorey; Fariba Goodarzian; Cecilia H Fu; Vicente Gilsanz
Journal:  Am J Clin Nutr       Date:  2012-03-28       Impact factor: 7.045

4.  Study of single nucleotide polymorphisms of tumour necrosis factors and HSP genes in nasopharyngeal carcinoma in North East India.

Authors:  Meena Lakhanpal; Laishram Chandreshwor Singh; Tashnin Rahman; Jagnnath Sharma; M Madhumangal Singh; Amal Chandra Kataki; Saurabh Verma; Santhi Latha Pandrangi; Y Mohan Singh; Saima Wajid; Sujala Kapur; Sunita Saxena
Journal:  Tumour Biol       Date:  2015-07-22

5.  Follicular lymphoma cell niche: identification of a preeminent IL-4-dependent T(FH)-B cell axis.

Authors:  C Pangault; P Amé-Thomas; P Ruminy; D Rossille; G Caron; M Baia; J De Vos; M Roussel; C Monvoisin; T Lamy; H Tilly; P Gaulard; K Tarte; T Fest
Journal:  Leukemia       Date:  2010-10-14       Impact factor: 11.528

6.  Influence of body mass index on survival in veterans with multiple myeloma.

Authors:  Tracey S Beason; Su-Hsin Chang; Kristen M Sanfilippo; Suhong Luo; Graham A Colditz; Ravi Vij; Michael H Tomasson; John F Dipersio; Keith Stockerl-Goldstein; Arun Ganti; Tanya Wildes; Kenneth R Carson
Journal:  Oncologist       Date:  2013-09-18

7.  TNF-α promoter polymorphisms and risk of recurrence in patients with squamous cell carcinomas of the nonoropharynx.

Authors:  Caiyun Zhang; Erich M Sturgis; Hongliang Zheng; Mark E Zafereo; Qingyi Wei; Guojun Li
Journal:  Int J Cancer       Date:  2014-02-27       Impact factor: 7.396

8.  Doxorubicin acts through tumor necrosis factor receptor subtype 1 to cause dysfunction of murine skeletal muscle.

Authors:  Laura A A Gilliam; Leonardo F Ferreira; Joseph D Bruton; Jennifer S Moylan; Håkan Westerblad; Daret K St Clair; Michael B Reid
Journal:  J Appl Physiol (1985)       Date:  2009-09-24

9.  The comparison of spontaneous LDH release activity from cultured PBMC with sera LDH activity in non-Hodgkin's lymphoma patients.

Authors:  V Jurisić; G Konjević; R Jancić-Nedeljkov; M Sretenović; B Banicević; M Colović; I Spuzić
Journal:  Med Oncol       Date:  2004       Impact factor: 3.064

10.  Developments in the imaging of brown adipose tissue and its associations with muscle, puberty, and health in children.

Authors:  Houchun H Hu; Vicente Gilsanz
Journal:  Front Endocrinol (Lausanne)       Date:  2011-09-22       Impact factor: 5.555

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.